This merger may mean the demise of MK-7009, MRK’s protease inhibitor, insofar as SGP’s Boceprevir is much further advanced and SGP also has a follow-on compound called SCH 900518 (#msg-35738787).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”